If prostate cancer has appeared in your family, or if you have recently been diagnosed, you may have heard that genetic testing is now recommended in certain situations. But what do those recommendations actually mean? Who qualifies? And what does the process look like?
This article explains the current clinical guidelines for genetic testing for prostate cancer: who should get tested, which genes matter, what a positive result means for your monitoring plan, and how to access testing even if your doctor has not brought it up yet.
What Is Genetic Testing for Prostate Cancer and Why Does It Matter?
Prostate cancer genetic testing looks at your inherited DNA: the DNA you were born with, present in every cell of your body, to identify gene mutations that may significantly elevate your lifetime prostate cancer risk.
This is different from a PSA test, which looks for signs that prostate cancer may already be present. Genetic testing identifies inherited risk present since birth, so you can make more informed decisions about proactive monitoring and care.
Knowing whether you carry an inherited gene mutation matters for two very different groups of men:
Men who have not been diagnosed: A positive result may mean starting PSA monitoring earlier, working with a specialist who understands hereditary prostate cancer, and having more informed conversations with your physician about your risk level.
Men who have been diagnosed: A positive result may directly affect treatment decisions, particularly for advanced or metastatic disease, where certain gene mutations may predict whether specific therapies are likely to work.
What Do the Guidelines Say?
The most widely followed guidelines in the United States come from the National Comprehensive Cancer Network (NCCN), which updates its prostate cancer guidelines annually. The American Urological Association (AUA) and the European Association of Urology (EAU) publish similar recommendations.
Here is what the current NCCN guidelines recommend:
For Men Who Have Not Been Diagnosed
NCCN recommends discussing germline genetic testing (meaning inherited DNA testing) with undiagnosed men who meet certain family history or ancestry criteria. See the full eligibility checklist in the infographic below.
For men who test positive for an inherited mutation, NCCN recommends beginning annual PSA monitoring as early as age 40, depending on the gene involved, a full decade earlier than the standard starting point for average-risk men.
For Men Who Have Been Diagnosed
NCCN recommends germline genetic testing for all men with metastatic prostate cancer, regardless of family history. It also recommends testing for men with high-risk or very high-risk localized prostate cancer who also have a relevant family history.
This matters because mutations in certain genes — particularly a BRCA2 mutation — may predict whether PARP inhibitor therapies are likely to be effective. Testing is not just about understanding risk. It may directly inform which treatments are worth pursuing.
Who Qualifies for Prostate Cancer Genetic Testing?
Your family history and personal health history are the two most important signals. Here is what the current guidelines say to look for:
Do You Qualify for Genetic Testing for Prostate Cancer?
Meeting any one of these criteria is enough to make genetic testing clinically appropriate according to NCCN guidelines.
A genetic counselor can confirm eligibility and recommend the right panel for your situation.
Family history criteria
A father or brother diagnosed with prostate cancer before age 60
Two or more first-degree relatives with prostate cancer at any age
A first-degree relative with a confirmed mutation in BRCA1 or BRCA2, or a Lynch syndrome gene
A family history of breast, ovarian, or pancreatic cancer alongside prostate cancer — this pattern may suggest a BRCA carrier family
Ancestry and inherited risk
Ashkenazi Jewish ancestry combined with any personal or family cancer history
A prostate cancer diagnosis with aggressive features, such as a high Gleason score 7 or higher, or intraductal carcinoma
Treatment decision criteria
Any prostate cancer diagnosis where results could affect treatment decisions, particularly for advanced or metastatic disease
Testing may help clarify inherited risk, guide screening for relatives, and support more informed care planning
You do not need a prostate cancer diagnosis to pursue genetic testing. Many men pursue it proactively because of their family history, and that is exactly the right time.
This infographic summarizes common hereditary prostate cancer testing criteria. A qualified clinician or genetic counselor should confirm what applies to your situation.
Source: NCCN, American Cancer Society
Which Genes Are Included in Prostate Cancer Genetic Testing?
A hereditary prostate cancer genetic panel tests multiple genes simultaneously from a single sample.
Here are the most clinically important ones and what each means:
BRCA2: The most significant hereditary prostate cancer gene. A mutation in BRCA2 may raise the lifetime risk of developing prostate cancer to between 19% and 61% by age 80, compared to approximately 10.6% in the general population. BRCA2-associated prostate cancers also tend to be more aggressive. Source: NCI BRCA Fact Sheet.
BRCA1: Carries a more modest prostate cancer risk elevation (approximately 7 to 26% lifetime risk), but is included in prostate cancer panels because of its broader hereditary cancer implications for the whole family.
Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2): These genes are most commonly associated with colorectal and endometrial cancer, but they also carry a moderate elevation in prostate cancer risk, approximately 2 to 5 times the general population average. (NCI, Genetics of Prostate Cancer)
HOXB13: A prostate-specific gene. A particular mutation in this gene, called G84E, is associated with early-onset hereditary prostate cancer and is found most commonly in men of Northern and Eastern European descent.
ATM and CHEK2: Both carry moderate prostate cancer risk elevation and are commonly included in comprehensive hereditary cancer panels.
PALB2: Primarily associated with breast and pancreatic cancer, with growing evidence for a moderate prostate cancer association.
When Should Men with Hereditary Risk Start PSA Monitoring?
Standard population monitoring guidelines, which typically recommend starting PSA discussions at age 50 for average-risk men, are not designed for men with confirmed inherited gene mutations or a significant family history.
The table below shows how the recommended starting age may change based on your specific risk level.
When Should You Start PSA Monitoring?
PSA screening timing changes based on family history, inherited risk, and confirmed cancer-related gene mutations.
Your Situation
Start PSA At
How Often
Why It Changes
No family history, no known gene mutation
Age 50
Per physician guidance
Standard population guideline for average-risk men
One first-degree relative with prostate cancer
Age 45
Annual discussion recommended
Modestly elevated risk warrants an earlier baseline PSA conversation
Multiple relatives OR relative diagnosed before age 55
Age 40 to 45
Annual testing recommended
A strong family history pattern suggests a hereditary component. NCCN recommends earlier surveillance.
Confirmed mutation in the BRCA2 gene from either parent
Age 40
Annual, per NCCN 2026
BRCA2-associated prostate cancers tend to be more aggressive. Earlier monitoring may make a meaningful difference.
A confirmed mutation in BRCA2 calls for annual PSA testing starting at age 40: a full decade earlier than standard guidelines.
Source: NCCN Prostate Cancer Early Detection Guidelines, Version 2.2026
What Happens After a Positive Genetic Test Result?
A positive result - meaning a harmful inherited gene mutation was identified - opens a set of clinical conversations and options that are simply not available to men who do not know their status:
Earlier PSA monitoring that starts at the age recommended for your specific gene mutation, as shown in the table above.
Specialist referral to a urologist with hereditary prostate cancer experience, who can provide more tailored surveillance than standard urology care.
Multi-cancer monitoring if relevant. A mutation in BRCA2 also elevates breast and pancreatic cancer risk. Lynch syndrome carriers face elevated colorectal and other cancer risks. A positive result triggers a broader conversation about your full inherited cancer risk picture, not just prostate cancer.
Family communication. All first-degree relatives — brothers, sons, sisters, and daughters — each have a 50% chance of carrying the same mutation. A genetic counselor helps you navigate what to share and when, so family members who may want to consider testing can make informed decisions.
Your genetic information is private and protected, accessible only to you and your care team.
What If My Doctor Has Not Brought This Up?
This happens more often than many men and their physicians realize. Prostate cancer genetic testing guidelines have evolved significantly since 2019, and not every physician is up to date on the latest recommendations or routinely discusses them with patients who meet the criteria.
If you think you may qualify based on the criteria above, here are your options:
Ask your urologist or primary care physician directly: 'Given my family history, do I qualify for hereditary prostate cancer genetic testing per NCCN guidelines?' This question gives your physician a clear, specific starting point.
Request a referral to a genetic counselor for a formal hereditary cancer risk assessment. A genetic counselor reviews your complete family history and advises whether testing is clinically appropriate.
Access testing through a precision health membership that provides direct access to hereditary cancer risk testing and genetic counseling without requiring a physician referral to initiate the process.
FAQ: Prostate Cancer Genetic Testing Guidelines
Is genetic testing for prostate cancer recommended for average-risk men?
No. Current clinical guidelines recommend prostate cancer germline genetic testing for men who meet specific family history or clinical criteria, not for the general male population. If you are unsure whether you meet the criteria, a genetic counselor can review your family history and advise accordingly.
Which guidelines should I follow?
The NCCN prostate cancer guidelines are the most widely referenced in U.S. clinical practice and are updated annually. The AUA and EAU publish their own guidelines with broadly similar recommendations. Your physician will typically refer to the NCCN guidelines in a U.S. clinical setting.
Is genetic testing for prostate cancer different from a PSA test?
Yes. They serve completely different purposes. A PSA test is a blood test that measures a protein produced by the prostate and may detect signs of prostate cancer that are already present. Genetic testing analyzes the DNA you were born with to identify inherited gene mutations that may elevate your lifetime cancer risk. Genetic testing may inform when to start PSA monitoring and how intensively to conduct it. The two tools work together, not as alternatives.
Can the results of prostate cancer genetic testing affect my family members?
Yes. If you test positive for an inherited gene mutation, each of your first-degree relatives — brothers, sons, sisters, and daughters — has a 50% chance of carrying the same mutation. Sisters and daughters can carry a BRCA2 mutation and may face elevated breast and ovarian cancer risk. A genetic counselor helps you understand what this means for your family and how to communicate results to relatives who may want to consider testing.
If You Meet the Criteria, the Right Time to Test Is Now
Clinical guidelines define who should be offered hereditary prostate cancer genetic testing based on current evidence. For men who meet the criteria, testing may provide a more complete picture of hereditary cancer risk, an earlier and more tailored surveillance plan, and, if cancer is ever diagnosed, results that could directly inform treatment decisions.
If prostate cancer runs in your family, you already know something matters. Genetic testing may tell you exactly what, and what to do about it.
Kadance members receive access to hereditary cancer risk testing covering 26 clinically actionable genes, including BRCA1, BRCA2, and the primary Lynch syndrome genes, through a CAP-accredited, CLIA-certified laboratory.
Every gene was selected because a positive result leads to a concrete next step.
Membership also includes genetic counseling to help interpret positive results and build a plan your physician can act on. Visit www.kadance.com to learn about current membership options.
The information in this article is intended for educational purposes only and does not constitute medical advice. It may not fully reflect the current scope of Kadance services, testing panels, or program offerings. For the most accurate and up-to-date information about what Kadance includes, please visit kadance.com or speak with a member of our team.
.svg)
